Orforglipron for treating moderate-to-severe sleep apnea in overweight or obese adults: Study design and starting patient data from a phase 3 trial

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Atul Malhotra reports financial support was provided by University of California San Diego (UCSD). Atul Malhotra reports a relationship with Eli Lilly that includes: consulting or advisory. Dr. Malhotra is funded by the NIH, including PI on R01 AG063925, R01 HL148436, R01 HL148436, R01 HL157985, R01 HL166485. He reports income from Livanova, Zoll, Sunrise, Eli Lilly and Company, and Powell Mansfield. He is co-founder and has equity in Clairyon a small startup related to predictive analytics. Resmed provided a philanthropic donation to UCSD in 2015. Livia Firmino Goncalves reports administrative support, statistical analysis, and writing assistance were provided by Eli Lilly and Company. Livia Firmino Goncalves reports a relationship with Eli Lilly and Company that includes: employment, equity or stocks, and non-financial support. Daniel J. Gottlieb reports financial support was provided by Eli Lilly and Company. Daniel J. Gottlieb reports a relationship with Signifier Medical Technologies, Inc. that includes: consulting or advisory. Daniel J. Gottlieb reports a relationship with Apnimed Inc that includes: consulting or advisory. Daniel J. Gottlieb reports a relationship with Takeda Development Center Americas Inc that includes: consulting or advisory. Daniel J. Gottlieb reports a relationship with Eli Lilly and Company that includes: consulting or advisory. Daniel J. Gottlieb reports income from Signifier Medical Technologies, Inc., Apnimed, Inc., Takeda Development Center Americas, Inc., and Eli Lilly and Company. Vaishnavi Kundel reports financial support was provided by Eli Lilly and Company. Vaishnavi Kundel reports a relationship with Apnimed Inc that includes: consulting or advisory. Vaishnavi Kundel reports a relationship with ZOLL Respicardia Inc that includes: consulting or advisory. Vaishnavi Kundel reports a relationship with Eli Lilly and Company that includes: consulting or advisory. Vaishnavi Kundel reports income from Eli Lilly and Company, Apnimed, and ZOLL Respicardia Inc. Holger Woehrle reports financial support was provided by Eli Lilly and Company. Holger Woehrle reports a relationship with Eli Lilly and Company that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Sujatro Chakladar reports financial support was provided by Eli Lilly and Company. Sujatro Chakladar reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks. Giulia Calamai reports financial support was provided by Eli Lilly and Company. Giulia Calamai reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks.